SimplyCast CEO Enters Atlantic Business Hall of Fame

 SimplyCast is marking a new milestone in its history, thanks to its President and CEO. SimplyCast is jubilant in announcing that President and CEO Saeed El-Darahali has been selected as one of Atlantic Canada’s Top 50 CEOs for the fifth consecutive year since 2020. This award honors excellence among Atlantic Canada’s enterprising business leaders who emphasize giving back to their communities while making advancements in their given industries. With this selection, Saeed is also being inducted into the Atlantic Business Magazine’s Hall of Fame.

Since 1999, Atlantic Business Magazine has dedicated one issue every year to the recognition and celebration of outstanding corporate leadership in Atlantic Canada. CEOs selected as Atlantic Canada’s Top 50 will be featured in the special May/June 2024 Top 50 Issue and online at the Atlantic Business Magazine. Those selected were honored at an annual awards gala on May 9, 2024, at the Delta St. John’s Hotel & Conference Centre.

El-Darahali said, “Entering the Hall of Fame alongside such esteemed and accomplished individuals is a profound experience. I credit much of this honor to the exceptional team at SimplyCast, whose dedication and innovation have propelled our growth. Their ideas and passion have been instrumental in shaping SimplyCast into what it is today. Witnessing their progress alongside the company has been a privilege. I extend my gratitude to Atlantic Business Magazine for consistently acknowledging our achievements over the years.”

During the Annual Awards Gala, the Top 50 CEOs were awarded, as well as a Presentation of Atlantic Canada Industry Builder, 2024 Hall of Fame Inductions, Stewart McKelvey Innovator of the Year and CEO of the Year.

This achievement for SimplyCast and El-Darahali continues to show the core values and guiding principles of the organization as it expands on its accolades, awards, and accomplishments. This includes El-Darahali’s honorary diploma from Nova Scotia Community College for outstanding work with youth retention and immigration with the OneNS Coalition that he received in 2022.

All these incredible successes for SimplyCast and El-Darahali haven’t changed them, as they have never forgotten their roots and the support they received from their community. SimplyCast continues to support many non-profit organizations and hires from all walks of life, investing time and training into bringing out the potential in its employees. SimplyCast champions students and new graduates via internships and co-ops that furnish them with the skills and confidence they need to build a bright future.

As they celebrate this new milestone, SimplyCast continues to look to the future, to honor their roots but to grow, creating a legacy for years to come.

About SimplyCast

SimplyCast is an ISO 27001, 27017, and 27018-certified leading provider of engagement software for organizations worldwide. Providing both emergency and non-emergency communication technology, SimplyCast offers 20+ communication tools and channels to help organizations maximize their efficiency. The company’s 360 engagement platform is a feature-rich solution combining marketing automation, inbound marketing, and interactive communication. With customers in over 175 countries, including many of the most recognized brand names around the globe in retail, non-profit, and hospitality industries, SimplyCast provides organizations the ability to effectively reach customers on their preferred mode of communication.

About Atlantic Business Magazine

Founded in 1989, Atlantic Business Magazine is a bi-monthly glossy consumer publication that covers all areas of business within the four Atlantic provinces. Since its founding in 1989, Atlantic Business Magazine has become the longest-publishing and most award-winning regional business magazine in Atlantic Canada and publishes a minimum of 35,000 copies per issue. Atlantic Business Magazine follows a controlled circulation model of distribution to reach business readers via The Globe & Mail, airport executive lounges, major hotels, and Marine Atlantic ferries. Its flagship issue of the year is its May/June celebration of corporate leadership excellence: the Top 50 CEO Awards.

Jodi Millington
902-835-8974 ext. 1225



  • Awards

Japan – HRC Enters CR ELECTRIC PROTO in International Electric Moto Racing Series

Honda Racing Corporation (HRC) announced that its factory team(1) “Team HRC” will race the CR ELECTRIC PROTO electric motocrosser in the FIM(2) E-Xplorer World Cup, an international electric all-terrain motorcycle racing series.

Team HRC will be represented by 2024 Dakar Rally rider Tosha Schareina (Spain, age 28) and Italian WMX champion Francesca Nocera (Italy, age 30).

Honda is committed to the electrification of motorcycles as the mainstay of its future environmental strategy, aiming to achieve carbon neutrality through all Honda-related products and corporate activities in 2050, and in all motorcycle products in the 2040s. In motorsports last year, Honda made a spot entry in the All Japan Motocross Championship (JMX) with the CR ELECTRIC PROTO, and it will continue to strengthen its technology by competing in new electric motorcycle races.

Koji Watanabe, President of Honda Racing Corporation

“As Honda’s commitment to carbon neutrality grows in importance, HRC has decided to enter the FIM E-Xplorer World Cup, a new category of electric off-road motorcycle racing in motorcycle motorsports. By taking on the challenge of a new electric motorcycle racing series, HRC will hone its technology in a real-world setting, accumulate know-how and knowledge, and further accelerate development of human resources. We hope you will look forward to Honda’s efforts.”


Team: Team HRC


#68 Tosha Schareina
#116 Francesca Nocera

Tosha Schareina
Birth date: March 6, 1995 (age 28)
Birthplace: Spain

Career highlights:
2021 Dakar Rally 2021: 13th
2023 Dakar Rally 2023: 13th
2024 Dakar Rally 2024: Participated

Francesca Nocera
Birth date: October 23, 1993 (age 30)Birthplace: Italy
Career highlights:
2015 Italian WMX Championship: Winner
2016 Italian WMX Championship: Winner
2017 Italian WMX Championship: 2nd
2019 Italian WMX Championship: Winner
2023 FIM Women’s Enduro World Championship: 3rd


The FIM E-Xplorer World Cup is a world series for electric off-road motorcycles that began in 2023, with mixed teams of men and women competing. This season’s competition will consist of a preliminary round for men and women, followed by three-heat races to determine the first to third place teams in a competitive format. Races will be held on special courses of partially dirt and partially paved asphalt surfaces. In the first year, Sandra Gomez and Jorge Zaragoza of the Japanese team Team MIE won the championship.For the second year, the series will be held in Asia for the first time, with the opening round to be held at the Expo’70 Commemorative Park‘s Festival Square in Suita City, Osaka Prefecture, on February 16 and 17. Subsequent rounds will be held in Norway, France, Switzerland, and India.

(1) Factory team: operated by manufacturer. Honda factory teams operated by Honda Racing Corporation (HRC)
(2) FIM: Fédération Internationale de Motocyclisme

For more details, visit FIM E-Xplorer World Cup’s official website:(https://

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. Enters the Gambling Software Provider Arena

 A prominent player in the betting software provider industry has announced its entrance into the market with the launch of This new platform aims to revolutionize how online bookies operate by offering personalized and professional assistance.

Led by a private investor with over 27 years of experience in Costa Rica’s offshore sportsbook scene, provides concierge-style support and scalable solutions for betting operators. The concept for the platform was born out of the founder’s observation of a gap in the market for personalized support.

The online sports sector has witnessed remarkable growth in recent years, driven by the surge in online betting. According to a report by ResearchAndMarkets, the global online sports betting market was valued at $24.4 billion in 2020 and is projected to reach $155.4 billion by 2028, with a notable CAGR of 28.3% during the forecast period.

With a growing demand for quality sports betting software solutions tailored to the needs of specific agents, BookieHelper offers a wide range of highly-customized services, including quick player setup and management of custom limits. It also provides turnkey solutions for bookies, complete with custom website design options. Moreover, they support seamless integration with third-party software, enabling easy adoption of payment processing solutions and API integration.

The platform boasts an impressive array of products, including pre-game sports betting markets, dynamic live betting providers, virtual casinos, live dealer casino solutions, premium racebook software, and props builder software. And their flexible pricing structure opens doors for small entrepreneurs who aspire to start their own bookmaking enterprises.

BookieHelper also offers call center services in English, Spanish, and Chinese. They also accept several payment methods, including cryptocurrencies, allowing customers to make payments safely and securely without compromising sensitive financial information.

“Our mission at is to provide professional support that exceeds our customers’ expectations. We believe in going the extra mile to ensure their success. We are dedicated to revolutionizing the betting software industry by offering scalable solutions and a rental model that empowers small entrepreneurs to thrive. Our customers can expect a partnership built on trust, innovation, and unwavering support.” – JC Hernandez, Founder.

With highly-customized services, scalable solutions, and a rental model that empowers small entrepreneurs, meets the evolving needs of sports and casino betting operators. Join on this exciting journey as they redefine the future of betting software.

Bookie Helper
JC Hernandez



  • Business
  • Casinos & Gambling
  • Small Business Services
  • Software
  • Technology

Japan – Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration

Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.

BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumor effects on breast, lung and other solid tumors that express HER2. The linker-payload, which uses eribulin as a payload, is a proprietary technology platform developed by Eisai’s U.S. research base Exton Site, and Eisai is investigating the possibilities of using this platform to link to various antibodies. Under a license agreement signed by the two companies in 2018, Eisai has granted BlissBio global exclusive development rights for several ADCs to use eribulin as the payload. Based on the status of the Phase I/II clinical trials of BB-1701 currently being conducted by BlissBio, the both companies have decided to co-develop this drug.

Under the terms of the joint development agreement, Eisai will make upfront and development milestone payments to BlissBio, conduct a Phase II clinical trial in breast cancer, and obtain option rights to develop and commercialize BB-1701 globally, excluding Greater China (China, Hong Kong, Macau, Taiwan). If Eisai exercises the option rights, an additional upfront payment will be made to BlissBio, as well as development and regulatory milestone payments, sales milestone payments and a certain amount of royalties on sales revenue of BB-1701 after the launch. If all development, regulatory and sales milestones are achieved, up to a total of $2 billion USD will be paid.

“BB-1701 is characterized by its payload of eribulin, which is a product of our modern synthetic organic chemistry that has already made contributions to patients with breast cancer and soft tissue sarcoma,” said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. “Our collaboration with BlissBio will accelerate the development of BB-1701 with the goal of bringing a new treatment option to patients globally.”

About Bliss Biopharmaceuticals (Hangzhou) Co., Ltd.

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”), is a clinical-stage biotech company dedicated on discovery, development and commercialization of anti-tumor biotherapeutics, founded by pharmaceutical veterans in 2017 in Hangzhou, Zhejiang province. BlissBio has established a unique and patented technical platform, a rich ADC-focusing pipeline, and GMP manufacture capability that could support antibody and ADC production for both clinical development and early commercialization. BlissBio has been nominated as a national high-tech biopharmaceutical enterprise in China. With “Together, We Improve Human Health” as the core value, through international and domestic collaborations, BlissBio will continue to focus on innovative drugs to address unmet medical needs.

For more information, please visit

About BB-1701 (development code)

BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumor effects on breast, lung and other solid tumors that express HER2 through multiplex mechanisms like direct cytotoxicity (including immunogenic cell death), a bystander effect* and immune response-induced cell death. BlissBio is currently conducting Phase I/II clinical trials in the U.S. and China for HER2-expressing solid tumors.

*Bystander effect: When the anticancer agent and antibody parts of an ADC are separated inside a targeted antigen-positive cancer cell, the released anticancer agent also affects neighboring antigen-negative cancer cells and the component cells of the cancer microenvironment.

For more information, visit

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Japan – Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on “Patient-Proposed Healthcare Services” System

Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name “Tazverik Tablets 200 mg”, “tazemetostat”) based on “Patient-Proposed Healthcare Services” system. This clinical research will be conducted by the National Cancer Center Hospital.

The “Patient-Proposed Healthcare Services” system is a system under which medical treatment using unapproved drugs not covered by insurance is applied for to the government based on the patient’s request, and is conducted as a clinical trial to confirm safety and efficacy. Under the terms of the agreement, Eisai will provide tazemetostat free of charge to the National Cancer Center Hospital as the drug to be used in “A clinical trial of Tazemetostat for pediatric and AYA* patients with malignant tumors which have no standard of care or and which is refractory to standard of care: Patients-Proposed Healthcare Service” to be conducted by the hospital under this program.

Researched and developed by Eisai and Epizyme, Inc.,** an Ipsen (Headquarters: France) company, tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process.1 Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of “relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)” in 2021, and manufactures and distributes the product.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai is committed to expanding the potential clinical benefits of tazemetostat for cancer treatment, as it seeks to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families and healthcare professionals.

*AYA (Adolescent & Young Adult): Patients between the ages of 15 and 39.
**Acquired by Ipsen in 2022

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.

For more information, visit

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.